Podcast

Speaking of Urology: How to get started with HIFU for prostate cancer

Author(s):

Urology Times staff

In this episode, Samuel J. Peretsman, MD, discusses how to get started with HIFU for prostate cancer and performing robotic prostatectomy following HIFU.

Listen to the rest of this interview:

Part 1: A HIFU expert discusses his treatment criteria

Part 2: What patients undergoing HIFU should expect postoperatively

Related Videos
Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
Rebecca A. Campbell, MD, answers a question during a Zoom video interview
Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
1 expert in this video
Comparing Trials Studying Treatment Intensification In mHSPC
An Overview of the ARANOTE Trial
An Overview of the ARANOTE Trial
Nitin Yerram, MD, on a liquid biopsy urine test for prostate cancer
Nitin Yerram, MD, on a liquid biopsy urine test for prostate cancer
Man talking with doctor | Image Credit: © Khunatorn - stock.adobe.com
Stephen J. Freedland, MD, on the benefits of mCRPC treatments translating to the real world
Preston Sprenkle, MD, highlights trial of TULSA vs radical prostatectomy
Preston Sprenkle, MD, highlights trial of TULSA vs radical prostatectomy
Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
Expert discusses the relationship between RCTs and real-world efficacy of prostate cancer treatments
Study data point to gender disparities in oncology research citations
Study data point to gender disparities in oncology research citations
Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
Related Content
Woman talking with a doctor online using digital tablet | Image Credit: © rh2010 - stock.adobe.com
May 15th 2025

Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

Tracey L. Krupski, MD Jeunice Owens-Walton, MD
"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
Pearls & Perspectives: Understanding and addressing priapism, with Serge Carrier, MD, and Gregory Broderick, MD
May 2nd 2025

Pearls & Perspectives: Understanding and addressing priapism, with Serge Carrier, MD, and Gregory Broderick, MD

Amy M. Pearlman, MD
Experts discuss urgent priapism management strategies, emphasizing timely intervention and collaboration for optimal patient outcomes.
Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC
May 6th 2025

Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC

Hannah Clarke
Initial study results may be available as soon as the first half of 2026.
Pearls & Perspectives: Evolving role of APPs in urology, with Corinna Hughes, DNP, at AUA 2025
May 1st 2025

Pearls & Perspectives: Evolving role of APPs in urology, with Corinna Hughes, DNP, at AUA 2025

Amy M. Pearlman, MD
Corinna Hughes, DNP, sits down with Amy Pearlman, MD, to discuss the evolving recognition of APPs in urology.
Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
Published: April 29th 2025 | Updated: April 29th 2025

Ultra-low PSA responses are more prevalent with darolutamide plus ADT

Benjamin P. Saylor
The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”
ARANOTE substudy highlights benefits of darolutamide in Black men
April 28th 2025

ARANOTE substudy highlights benefits of darolutamide in Black men

Benjamin P. Saylor
The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in Black men.
© 2025 MJH Life Sciences

All rights reserved.